Cambridge, UK and Indianapolis, US – 21 April 2021, 07:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, is proud to be named a new Industry Supporter of the American Society of Anesthesiologists (“ASA” or the “Society”).
Launched in 2010, ASA’s Industry Supporter Program is limited to ten organizations. Participation is intended for companies who want to stand apart by showcasing high-level commitment to the education of physician anesthesiologists, the anesthesia care team and advancement of the specialty.
As an Industry Supporter, Acacia Pharma will help to establish a strong, mutually beneficial relationship with the anesthesiology community, strengthen collaboration between physician anesthesiologists and industry, and add to the value the Society provides to patients and the public, while providing invaluable year-round support of ASA programs and priorities related to improving perioperative care.
Through the program, Acacia Pharma will have unique opportunities to inform strategic dialogue with leaders in anesthesiology from around the world and during major ASA events including the ANESTHESIOLOGY® annual meeting and Practice Management™ conference.
Acacia Pharma has two FDA-approved anesthesiology products currently being launched in the U.S. The first is a new dopaminergic antiemetic approved for treatment and prophylaxis of postoperative nausea and vomiting (PONV), targeted at addressing the major unmet need in the rescue treatment of patients suffering with PONV. The second is a novel, rapid on/rapid off and reversible benzodiazepine approved for procedural sedation in adults undergoing procedures lasting up to 30 minutes, such as colonoscopy and bronchoscopy.
“We are excited to welcome Acacia Pharma as a new ASA Industry Supporter,” said ASA President Beverly K. Philip, M.D., FACA, FASA. “By working with our Industry Supporters, we aim to improve perioperative care. Acacia Pharma and our members working together will strengthen the Society’s priorities of advancing the specialty through patient safety and practice initiatives.”
“We are delighted to become an ASA Industry Supporter, the world’s pre-eminent organization representing anesthesiologists,” commented Acacia Pharma Chief Medical Officer Gabriel Fox, M.D. “This gives us a greatly valued opportunity to work with anesthesiologists across the country to improve the safety, outcomes and well-being of their patients. We look forward to a successful partnership for years to come and thank ASA for this opportunity.”
About The American Society Of Anesthesiologists
Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 54,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.